Site-specific adaptive nanovesicles for oral insulin delivery
Science Advances · 26.09.2025 · 11 (39)
DOI: 10.1126/sciadv.ady6386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.09.2025. Verfasst von Bozhang Xia und 19 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience …. Hauptthemen laut MEDLINE: Insulin, Nanoparticles, Drug Delivery Systems. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Oral delivery of insulin holds great promise for improving patient compliance. However, the harsh gastrointestinal environment, the low permeability of the intestinal epithelium, and hepatic clearance of foreign particles remain key challenges in this area. Here, we report the site-specific adaptive milk-derived nanovesicles (MiNVs) capable of overcoming intestinal and hepatic barriers for oral insulin delivery. These MiNVs could bind natural IgG on their surface, enabling FcRn-mediated transcytosis by evading the lysosomal degradation pathway. Upon reaching the liver, MiNVs responded to the elevated levels of biothiols in the hepatic microenvironment, triggering site-specific insulin release. In type 1 diabetic rats, the oral bioavailability reached 20.4%, which is about 20-fold higher than that of free insulin. Notably, MiNVs showed effective glycemic control over long-term treatment in type 1 diabetic rat and minipig models. By integrating transepithelial transport and liver-specific responsiveness, the site-specific adaptability of MiNVs supports their promise in oral insulin administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beiji…
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133 Italy.
- Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, Beijing 100083, P. R. China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P. R. China.
- National Vaccine and Serum Institute (NVSI), China National Biotech Group (CNBG), No. 38 Jing Hai Second Road, Beijing, 101111, P. R. China.
ORCID-Profile: Bozhang Xia, Fengfei Xu, Junge Chen, Shaobo Shan, Jiuheng Shen, Yuxuan Zhang, Ziran Zhou, Weilun Sun, Ya-Li Zhang, Jie Zhong, Wenlin An, Yubo Fan, Massimo Bottini, Jinqiang Wang, Xing-Jie Liang
Zitieren
APA
Xia, B., Xu, F., Chen, J., Shan, S., Shen, J., Zhang, Y., Wang, J., Zhou, Z., Sun, W., Jia, Y., Zhang, Y. L., Zhong, J., Zhang, G., Wan, Y., Hu, Z., An, W., Fan, Y., Bottini, M., Wang, J., & Liang, X. J. (2025). Site-specific adaptive nanovesicles for oral insulin delivery. Science Advances, 11(39). https://doi.org/10.1126/sciadv.ady6386
Vancouver
Xia B, Xu F, Chen J, Shan S, Shen J, Zhang Y, et al. Site-specific adaptive nanovesicles for oral insulin delivery. Science Advances. 2025;11(39). doi:10.1126/sciadv.ady6386
BibTeX
@article{Xia2025,
author = {Xia, Bozhang and Xu, Fengfei and Chen, Junge and Shan, Shaobo and Shen, Jiuheng and Zhang, Yuxuan and Wang, Jinjin and Zhou, Ziran and Sun, Weilun and Jia, Yaru and Zhang, Ya-Li and Zhong, Jie and Zhang, Gang and Wan, Yichen and Hu, Zhongbo and An, Wenlin and Fan, Yubo and Bottini, Massimo and Wang, Jinqiang and Liang, Xing-Jie},
title = {Site-specific adaptive nanovesicles for oral insulin delivery},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {39},
doi = {10.1126/sciadv.ady6386}
}
EUVIMED